ROCKVILLE, Md., April 20, 2016 /PRNewswire/ -- N&N Pharmaceuticals Inc. (N&N) is a privately held biopharmaceutical company located in the biotech hub of Montgomery County, MD. Today, N&N announced the beginning of Phase I Clinical Trials of their novel antiviral drug, N-Methanocarbathymidine (known as N-MCT). These trials will define the safety and pharmacokinetic of the drug. The trials are currently taking place at Georgetown University Hospital, Division of Infectious Diseases. Dr. Princy Kumar will serve as Principal Clinician during this period.
Dr. Aquilur Rahman, President and CEO of N&N, commented, "We are highly pleased to begin these clinical trials of this novel antiviral drug. We have seen a high spectrum of activity of this drug in multiple viral diseases. N-MCT has shown significant activity in Shingles, Genital Herpes, Neonatal Herpes and in Small Pox." He added that the company will "pursue Shingles as the first indication for N-MCT. In pre-clinical studies with Shingle models, N-MCT has shown significantly more pronounced antiviral activity than any other known commercially available drug on the market."
He continued to note that "the Asian subsidiary of N&N, located in Korea, will soon start clinical trials of this wide spectrum antiviral agent N-MCT. We hope to expedite the clinical trials in Korea in the upcoming months; the data will supplement the clinical data being gathered and generated in the U.S. There are a significant number of Shingle cases in Korea, amounting to about 460,000 per year. In the U.S., about one million cases of Shingles have been reported annually. Thus, we hope to prioritize the clinical evaluation of N-MCT's activity on this particular disease, and look forward to a swift drug development and commercialization with the coordination of U.S. and Asian clinical trials."
Company Contact: Naveed Rahman Director of Business Development 301-250-7573 [email protected]
This press release contains forward looking statements within the meaning of "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995, including statements regarding the clinical trials and overall development plan of this drug for the clinic by the company cannot be taken for granted. Hence the company is not liable for change in any circumstances during the clinical and commercial development of this drug.